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siRNA has been widely used to identify gene functions and holds
great potential in providing a new class of therapeutics.1 The lack
of efficient delivery systems is limiting the full therapeutic potential
of siRNA technology and represents a challenging hurdle in this
field of therapy. For the purpose of nucleic acid transfer, among
other synthetic carrier systems, polycations have been applied for
the incorporation of plasmid DNA (pDNA) into polyplexes. Poly-
L-lysine (PLL) was one of the first polycations used for polyplex
formation. At physiological pH the amino groups of PLL are
positively charged and interact ionically with the negatively charged
nucleic acid which protects the nucleic acid and condenses it into
nanoparticles.2 An additional asset is the biodegradability of PLL
due to its peptidic nature. However, PLL shows almost no siRNA
and pDNA transfer activity. Cellular uptake of polyplexes is
effective, but the subsequent escape from endosomes into the
cytoplasm presents a major bottleneck. Over the past decade
polyethylenimines (PEIs) have evolved into currently the most
frequently used polycations. In contrast to PLL, PEI can promote
its escape to the cytosol from endosomes via the “proton sponge
effect”, and significant pDNA transfer efficiency can be observed
in vitro and in vivo.3,4 But in the case of siRNA transfer, PEI like
PLL shows only modest delivery activity. Here a modification of
these polycations is presented yielding polymers which are effective
in siRNA delivery.
The approach includes functionalization with polyethylene glycol
(PEG) and a pH-responsive endosomolytic melittin peptide, the
major bioactive component of the bee venom. Membrane active
peptides like melittin have shown to enhance gene transfer.5,6 Lytic
activity in the extracellular environment however is unfavorable
and triggers toxic side effects. Endosomal acidification is exploited
for a triggered activation of the lytic activity in the intracellular
compartment. The amines of melittin (Mel) are modified with
dimethylmaleic anhydride (DMMAn) which minimizes lytic activity
and hence toxicity at extracellular neutral pH. After endosomal
acidification the DMMAn protecting groups are cleaved and lytic
activity is restored.7,8 This principle enables the nucleic acid carrier
to adapt its behavior to the different needs of extra- and intracellular
delivery steps.
We observed that covalent modification of a polycation with a
necessary high density of negatively charged lytic peptides like
DMMAn-Mel or influenza peptide can lead to polymer collapse
and formation of large aggregates (>1 ím) after mixing with nucleic
acids. However, small nanoparticles are favorable for delivery. To
overcome this drawback, hydrophilic PEG was grafted onto the
polycation prior to peptide attachment which allowed formation of
small nucleic acid complexes. PEGylation of polyplexes was
previously found advantageous in terms of stability and in vivo
behavior including pharmacokinetics and tolerability.9
PLL (hydrobromide, MW 32 000) and PEI (branched, MW
25 000) were PEGylated with mPEG-succinimidyl propionate (MW
5000). The PEGylated polycations were further modified with
heterobifunctional N-succinimidyl 3-(2-pyridyldithio)propionate al-
lowing subsequent coupling of DMMAn-Mel peptide via the
N-terminal cysteine. The resulting conjugates had molar ratios of
approximately 1/1/8 for PLL/PEG/DMMAn-Mel and 1/1,5/8 for
PEI/PEG/DMMAn-Mel. A schematic structure of the synthesized
carriers is shown in Figure 1.
Interaction of the conjugates with siRNA was confirmed by an
ethidium bromide exclusion assay. The small sizes of the siRNA
polyplexes are shown in Table 1.
Next, siRNA delivery efficiency of the conjugates was examined
with the Neuro 2A-eGFPLuc cell line (mouse neuroblastoma stably
expressing luciferase). Luciferase siRNA was complexed with PLL
or PEI conjugates in a HEPES-buffered glucose solution.
The experiments were carried out with each polymer bound to
500ng luciferase siRNA at different ratios. 48 h after initial
transfection of 5000 seeded cells, the cells were lysed and assayed
for luciferase expression.
As shown in Figure 2, neither PLL nor PEI (with or without
PEG) mediated siRNA knockdown. But after modification with
DMMAn-Mel siRNA delivery efficiency was greatly enhanced as
demonstrated by luciferase gene knockdown. In parallel, complexes
with a control siRNA sequence were applied (white bars): if
luciferase expression decreases upon transfection with control
siRNA (as observed for PLL-PEG), “knockdown” is mainly due
to carrier toxicity and can hereby be distinguished from a real
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Figure 1. Schematic structure of the pH-responsive endosomolytic poly-
cation-PEG-DMMAn-Mel nucleic acid carrier. Endosomal acidification
triggers fast cleavage of the dimethylmaleic anhydride protecting groups
and restores lytic activity of melittin.
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siRNA knockdown effect. Metabolic activity was also assayed at
the end of transfection and confirmed the high viability of the cells
treated with DMMAn-Mel conjugate polyplexes.
The efficiency of pDNA delivery was also tested on Neuro 2A
cells (see Supporting Information). Unmodified PEI showed 30-
fold better gene transfer compared to unmodified PLL. PEGylation
had a disastrous effect: PEI lost its gene transfer activity to a
background like PEG-PLL. But after attachment of DMMAn-Mel
to PEI-PEG gene transfer activity was restored. In the case of PLL
modification with PEG and DMMAn-Mel gene transfer was enabled
reaching levels similar to those for PEI.
In summary, application of DMMAn-Mel combined with PEG
strongly enhanced siRNA delivery efficiency of the polycations.
Although the chemistry is different, these findings fit well to
recently published work on other bioresponsive and PEGylated
siRNA carriers.10-12 Remarkably, despite big differences of the
unmodified polycations in pDNA transfer activity, pDNA transfer
activity of PLL-PEG-DMMAn-Mel was similar to that for the PEI
analogue and even better in the case of siRNA transfer (for reasons
that remain to be explored). But in contrast to the PEI analogue,
PLL has the additional advantage of being biodegradable. As
previously shown, conjugation of DMMAn-Mel (in contrast to
unmasked melittin, or PEGylation only) considerably lowered the
acute cytotoxicity of the polycation PLL.8
These findings have implication for the selection of novel
polymers for siRNA delivery: polycations with favorable basic
characteristics such as nucleic acid binding, compaction, protection,
and biocompatibility, but poor delivery activity which obviously
would fail in high-throughput screenings13 might nevertheless be
converted into highly efficient siRNA carriers.
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Table 1. Size of the siRNA Polyplexesa
PEI/siRNA (w/w ) 1/1, m/m ) 1/1,9) 26 ( 8 nm
PLL /siRNA (w/w ) 2/1, m/m ) 1/1,2) 18 ( 9 nm
PEI-PEG/siRNA (w/w ) 1/1, m/m ) 1/1,9) 15 ( 8 nm
PLL-PEG/siRNA (w/w ) 2/1, m/m ) 1/1,2) 7 ( 1 nm
PEI-PEG-DMMAn-Mel/siRNA
(w/w ) 1/1, m/m ) 1/1,9)
25 ( 4 nm
PLL-PEG-DMMAn-Mel/siRNA
(w/w ) 2/1, m/m ) 1/1,2)
40 ( 26 nm
a Polycation/siRNA ratio w/w, weight/weight; m/m, mol/mol; size
determined by fluorescence correlation spectroscopy.
Figure 2. siRNA gene silencing efficiency (gray bars) on stably luciferase
expressing Neuro 2A-eGFPluc cells of PLL- and PEI-based conjugates
complexed with 500ng siRNA at different polycation/siRNA ratios. White
bars indicate transfection with complexes containing control siRNA.
Reduced gene expression with control siRNA indicates unspecific knockdown/
carrier toxicity.
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